JPMorgan Chase & Co. Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

JPMorgan Chase & Co. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,515,534 shares of the specialty pharmaceutical company's stock after selling 22,788 shares during the quarter. JPMorgan Chase & Co. owned 2.51% of Jazz Pharmaceuticals worth $168,846,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after buying an additional 121 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after buying an additional 704 shares during the period. Finally, Signaturefd LLC lifted its stake in Jazz Pharmaceuticals by 273.4% during the 3rd quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company's stock worth $169,000 after acquiring an additional 1,110 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 0.1 %

Jazz Pharmaceuticals stock traded up $0.18 during mid-day trading on Wednesday, hitting $123.15. The company had a trading volume of 442,346 shares, compared to its average volume of 668,536. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The business has a fifty day moving average of $120.50 and a 200 day moving average of $113.56. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of 17.35, a PEG ratio of 1.04 and a beta of 0.57.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. Piper Sandler reiterated an "overweight" rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock valued at $816,289 in the last ninety days. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.